phosphatidylethanolamine binding protein 1 pseudogene 3Genealiases: []
Q-omics provides the consensus-scored PEBP1P3 profile across patient tissues and cancer cell-line models. PEBP1P3 expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in UCS. Among the 18 cancer types available for tumor–normal comparison, PEBP1P3 is differentially expressed in 7, with the highest sampling consensus in LUSC. Additionally, PEBP1P3 RNA expression shows 21,218 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight UCS, LUSC, and LSCC as cancer lineages where PEBP1P3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PEBP1P3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PEBP1P3 survival associations across molecular data types. PEBP1P3 RNA expression shows survival associations in the most cancer types (18). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PEBP1P3 RNA expression–survival associations across cancer types. High PEBP1P3 expression shows unfavorable associations in KIRC and LGG, but favorable associations in UCS, BLCA, HNSC and SKCM. The UCS Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .005). Together, the overview and detailed table identify UCS as the clearest survival context for PEBP1P3 RNA expression.
This table summarizes PEBP1P3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for PEBP1P3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PEBP1P3 shows lower tumor expression in LUSC, THCA, BRCA, STAD, LUAD and KICH. The LUSC box plot shows higher PEBP1P3 RNA expression in normal versus tumor tissue (log2 FC = −0.265, t-test p = .001).
This table shows molecular features associated with PEBP1P3 in patient tissues and cancer cell lines. In patient samples, PEBP1P3 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set.
